←Back to Expert Scholars
Translational Medicine / 转化医学Milestone IO Approvals
Antoni Ribas
MD, PhD
🏢UCLA Jonsson Comprehensive Cancer Center🌐USA
Professor, Director Tumor Immunology Program
160
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Antoni Ribas led KEYNOTE-006 establishing pembrolizumab as standard therapy for advanced melanoma and has been a leader in defining mechanisms of primary and acquired resistance to immunotherapy. He directs the Tumor Immunology Program at UCLA Jonsson Comprehensive Cancer Center.
Share:
🧪Research Fields 研究领域
pembrolizumab melanoma
KEYNOTE-006
TIL therapy
IO resistance
cancer immunology
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Antoni Ribas 的研究动态
Follow Antoni Ribas's research updates
留下邮箱，当我们发布与 Antoni Ribas（UCLA Jonsson Comprehensive Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment